Desta Z, El-Boraie A, Gong L, Somogyi AA, Lauschke VM, Dandara C, et al. PharmVar GeneFocus: CYP2B6. Clin Pharmacol Ther. 2021;110(1):82–97.
CAS PubMed Article Google Scholar
Wang H, Tompkins L. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab. 2008;9(7):598–610.
CAS PubMed PubMed Central Article Google Scholar
Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008;82(10):667–715.
CAS PubMed Article Google Scholar
Mo S-L, Liu Y-H, Duan W, Wei M, Kanwar J, Zhou S-F. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab. 2009;10(7):730–53.
CAS PubMed Article Google Scholar
Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016;6(5):413–25.
PubMed PubMed Central Article Google Scholar
Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34(1–2):83–448.
CAS PubMed Article Google Scholar
Tornio A, Backman JT. Cytochrome P450 in pharmacogenetics: an update. Adv Pharmacol. 2018;83:3–32.
CAS PubMed Article Google Scholar
Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, Hockings J, Myers A, Swart M, Tyndale RF, Masimirembwa C, Iwuchukwu OF, Chirwa S, Lennox J, Gaedigk A, Klein TE, Haas DW. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2B6 and efavirenz-containing antiretroviral therapy. Clin Pharmacol Ther. 2019;106(4):726–33.
Krayenbühl JC, Vozeh S, Kondo-Oestreicher M, Dayer P. Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol. 1999;55(8):559–65.
Peters SA, Dolgos H. Requirements to establishing confidence in physiologically based pharmacokinetic (PBPK) models and overcoming some of the challenges to meeting them. Clin Pharmacokinet. 2019;58(11):1355–71.
CAS PubMed PubMed Central Article Google Scholar
Frechen S, Rostami-Hodjegan A. Quality assurance of PBPK modeling platforms and guidance on building, evaluating, verifying and applying PBPK models prudently under the umbrella of qualification: why, when, what, how and by whom? Pharm Res. 2022. https://doi.org/10.1007/s11095-022-03250-w.
Reddy VP, Walker M, Sharma P, Ballard P, Vishwanathan K. Development, verification, and prediction of osimertinib drug-drug interactions using PBPK modeling approach to inform drug label. CPT Pharmacometrics Syst Pharmacol. 2018;7(5):321–30.
Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther. 2006;316(1):336–48.
CAS PubMed Article Google Scholar
Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46(8):681–96.
CAS PubMed Article Google Scholar
Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet. 2008;47(10):669–80.
CAS PubMed Article Google Scholar
Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, Charpiat B. Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions. Clin Pharmacokinet. 2011;50(8):519–30.
CAS PubMed Article Google Scholar
Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M. In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. AAPS J. 2013;15(2):415–26.
CAS PubMed PubMed Central Article Google Scholar
Castellan AC, Tod M, Gueyffier F, Audars M, Cambriels F, Kassaï B, Nony P, Genophar Working Group. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure. Clin Pharmacokinet. 2013;52(3):199–209.
CAS PubMed Article Google Scholar
Gabriel L, Tod M, Goutelle S. Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers. Clin Pharmacokinet. 2016;55(8):977–90.
CAS PubMed Article Google Scholar
Di Paolo V, Ferrari FM, Poggesi I, Quintieri L. A quantitative approach to the prediction of drug-drug interactions mediated by cytochrome P450 2C8 inhibition. Expert Opin Drug Metab Toxicol. 2021;17(11):1345–52.
PubMed Article CAS Google Scholar
Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, Li Q, Zhang W, Wang G, Lei HP, Hu DL, Wang D, Zhou HH. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol. 2009;65(4):403–9.
CAS PubMed Article Google Scholar
Kustra R, Corrigan B, Dunn J, Duncan B, Hsyu P-H. Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion. J Clin Pharmacol. 1999;39(11):1184–8.
Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77(6):553–9.
CAS PubMed Article Google Scholar
Jiang F, Desta Z, Shon JH, Yeo CW, Kim HS, Liu KH, Bae SK, Lee SS, Flockhart DA, Shin JG. Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. Br J Clin Pharmacol. 2013;75(1):244–53.
CAS PubMed Article Google Scholar
McCance-Katz EF, Gruber VA, Beatty G, Lum P, Ma Q, Difrancesco R, Hochreiter J, Wallace PK, Faiman MD, Morse GD. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2014;23(2):137–44.
Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2003;74(4):326–33.
CAS PubMed Article Google Scholar
Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, Liechti ME. Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther. 2015;353(1):102–11.
CAS PubMed Article Google Scholar
Kirby BJ, Collier AC, Kharasch ED, Dixit V, Desai P, Whittington D, Thummel KE, Unadkat JD. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos. 2011;39(12):2329–37.
CAS PubMed PubMed Central Article Google Scholar
Evaluation D, Documents A. Center for drug evaluation and application number: 2010;(2004):21–3.
Wang J, Zhang ZY, Lu S, Powers D, Kansra V, Wang X. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects. Support Care Cancer. 2019;27(3):819–27.
Peltoniemi MA, Saari TI, Hagelberg NM, Reponen P, Turpeinen M, Laine K, Neuvonen PJ, Olkkola KT. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther. 2011;90(2):296–302.
CAS PubMed Article Google Scholar
Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol. 2013;53(3):305–13.
PubMed PubMed Central Article CAS Google Scholar
Desta Z, Metzger IF, Thong N, Lu JBL, Callaghan JT, Skaar TC, Flockhart DA, Galinsky RE. Inhibition of cytochrome P450 2B6 activity by voriconazole profiled using efavirenz disposition in healthy volunteers. Antimicrob Agents Chemother. 2016;60(11):6813–22.
CAS PubMed PubMed Central Article Google Scholar
Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol. 2008;48(8):948–56.
CAS PubMed Article Google Scholar
Fda. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212839Orig1s000 OTHER REVIEW(S).
Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr. 2008;49(5):513–9.
CAS PubMed PubMed Central Article Google Scholar
Kharasch ED, Whittington D, Ensign D, Hoffer C, Bedynek PS, Campbell S, Stubbert K, Crafford A, London A, Kim T. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2012;91(4):673–84.
CAS PubMed Article Google Scholar
Fahmi OA, Shebley M, Palamanda J, Sinz MW, Ramsden D, Einolf HJ, Chen L, Wang H. Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ Consortium induction working group—an industry perspective. Drug Metab Dispos. 2016;44(10):1720–30.
留言 (0)